Predict your next investment

Nutcracker Therapeutics company logo
HEALTHCARE | Biotechnology
nutcrackerx.com

See what CB Insights has to offer

Founded Year

2018

Stage

Grant | Alive

Total Raised

$74.46M

Last Raised

$460K | 7 mos ago

About Nutcracker Therapeutics

Nutcracker has engineered a push-button mRNA synthesis and formulation platform.

Nutcracker Therapeutics Headquarter Location

5858 Horton Street Suite 540

Emeryville, California, 94608,

United States

510-473-8478

Latest Nutcracker Therapeutics News

VCs have finally started paying attention to infectious diseases. Meet 6 up-and-coming biotechs tackling the pandemic pathogens of today and tomorrow.

Feb 4, 2021

Prominent backers: ARCH Ventures, Gates Foundation Founded in 2016, South San Francisco-based Vir received $14 million from the Gates Foundation in 2018 for a low-cost tuberculosis vaccine. The company, backed by ARCH Ventures, went public in late 2019 – months before the coronavirus pandemic. Aside from antibody treatments VIR-7831 and VIR-7832, its product pipeline includes several drug candidates treating hepatitis B, influenza A, HIV, and TB. Among the first biotechs to respond to the coronavirus last January, the publicly traded company benefited from a $250 million investment from GlaxoSmithKline last April. The product of that partnership, antibody VIR-7831, is currently being tested as part of a drug cocktail with Lilly's neutralizing antibody bamlanivimab. The drug was initially tested this fall in an efficacy-focused trial. In January, GSK announced a second GSK-Vir antibody, VIR-7832, would be tested in early-stage clinical trials in the UK. In early January, the company announced it had begun early clinical trials of its HIV vaccine candidate developed with support from Oregon Health & Science University and the Gates Foundation. On January 26, an early clinical study of its hepatitis B antibody showed it markedly reduced antigen levels in chronic hepatitis B patients. Greenlight Biosciences is making cheaper, commercial level production of mRNA a reality for vaccines. The Greenlight Biosciences team. Prominent backers: 5Y Capital, formerly known as Morningside Ventures, Gates Foundation Founded in 2008, Boston-based Greenlight Biosciences says it has developed a commercial method to produce mRNA for both life and plant sciences applications without the use of cells. Typically, mRNA production for academic research requires the use of cell culture. It's a time-consuming, specialized process that is not able to be reproduced at a larger scale. Two of the leading coronavirus vaccines — made by Pfizer/BioNTech and Moderna — use mRNA. In June, Greenlight raised a $102 million Series D, bringing its total funding to $215 million. In September, the company also received $3.3 million from the Gates Foundation to develop mRNA-based therapies for sickle-cell disease. CEO Andrey Zarur told CNBC in November that Greenlight also had its own preclinical COVID-19 vaccine in the works. In January, Zarur penned an op-ed for STAT , urging the biotech industry to collaborate. "Now is not the time for those involved in developing and manufacturing Covid-19 vaccines to hold their cards tightly to their chests," Zarur said in the op-ed. "We must work together and commit to helping each other. "  Adagio Therapeutics is developing antibody treatments for future emergent coronaviruses — not just SARS-CoV-2. Tillman Gerngross, CEO and cofounder of Adagio Therapeutics. Courtesy of Adagio Thereapeutics Prominent backers: GV (formerly known as Google Ventures) Waltham, Massachusetts-based Adagio is developing a host of broad-reaching antibody candidates that would treat SARS-CoV-2, the virus that causes COVID-19, as well as other emergent coronaviruses. The startup raised $80 million in a Series B backed by GV in November. On January 25, the company announced preclinical study results on its lead antibody candidate, ADG2, showing potential to protect against the current coronavirus as well as future strains. Adagio also said a modified version of ADG2, named ADG20, would begin Phase 1 clinical studies sometime early in 2021. The company's chief scientific officer Laura Walker said in its most recent press release  that ADG20 binds to a portion of the antigen molecule that is conserved among different coronaviruses, meaning that the molecule has the potential to be effective against future coronaviruses. "We were impressed by the thoughtful approach that Adagio took," GV life sciences head Krishna Yeshwant said in the Series B press release in November. "By dealing with the broader coronavirus problem, we expect ADG20 to be more resistant to escape mutations and potentially cover future coronavirus pandemics,"  Nutcracker Therapeutics' fully automated mRNA production process could help scale mRNA vaccine production for future pandemics. Igor Khandros, founder and CEO of Nutcracker Therapeutics. Courtesy of Nutcracker Therapeutics Prominent backers: ARCH Ventures Emeryville, California-based Nutcracker raised a $60 million Series B round last September led by ARCH Ventures, bringing it closer to commercializing its mRNA manufacturing platform. Like Greenlight Biosciences, its technology has the potential to contribute to the production of mRNA-based therapeutic interventions like the COVID-19 vaccines by Moderna and Pfizer. Using semiconductor manufacturing techniques, Nutcracker believes its fully automated ACORN platform, which produces mRNA molecules on single-use biochips, has the potential to efficiently produce mRNA-based drugs at large scale. Through automated mRNA production, Nutcracker's ACORN platform could accelerate the production of future mRNA treatments for current and future infectious diseases. A cow in a field. Photo by Soeren Stache/picture alliance via Getty Images Prominent backers: Merck, BARDA, Department of Defense For SAB Biotherapeutics, immunotherapy is the name of the game. With headquarters in both Sioux Falls, South Dakota and Cambridge, Massachusetts, SAB intends to use the body's natural defenses to treat autoimmune disorders and infectious disease. To do this, SAB uses genetically modified cows to develop neutralizing antibodies via their blood plasma. Although the company raised a $14 million Series B round last July, SAB's largest windfall has come from the Department of Defense and BARDA. In November, the US government gave SAB $57.5 million to manufacture SAB-185, the company's clinical stage COVID-19 antibody therapeutic. Via the same bovine genetic engineering, the company has two additional infectious disease drug candidates treating the flu and Middle East respiratory syndrome in early clinical stages. Sherlock Biosciences wants to make a low-cost, instrument free COVID-19 test a reality in 2021. Sherlock's coronavirus test.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Nutcracker Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Nutcracker Therapeutics in 1 CB Insights research brief, most recently on Feb 3, 2021.

Expert Collections containing Nutcracker Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nutcracker Therapeutics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Nutcracker Therapeutics Patents

Nutcracker Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Good practice
  • Life sciences industry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/10/2020

Pharmaceutical industry, Sensors, Good practice, Life sciences industry, Biotechnology

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/10/2020

00/00/0000

Grant Date

00/00/0000

Title

Subscribe to see more

Related Topics

Pharmaceutical industry, Sensors, Good practice, Life sciences industry, Biotechnology

Subscribe to see more

Status

Application

Subscribe to see more

Nutcracker Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Nutcracker Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.